What cell type is implicated in the inflammatory response with pulmonary sarcoidosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Macrophages and T cells, specifically CD4+ T cells, are implicated in the inflammatory response with pulmonary sarcoidosis.

Key Cell Types

  • Macrophages: form the central core of granulomas and are accompanied by multinucleated giant cells 1
  • T cells: CD4+ T cells play a central role in the immune response, with an accumulation of these cells and release of IL2, followed by the formation of non-caseating granulomas 1

Inflammatory Response

  • The inflammatory response in pulmonary sarcoidosis is characterized by the formation of non-caseating granulomas, which are composed of immune cells, including macrophages and T cells 1
  • The granulomas are often surrounded by a sparse lymphocytic infiltrate, and the presence of TH1 cytokines, such as interferon, and tumor necrosis factor (TNF) contribute to the inflammatory response 1

Clinical Implications

  • The diagnosis of pulmonary sarcoidosis is often established through histological evaluation of tissue granulomas, which typically show well-formed, concentrically arranged layers of immune cells 1
  • The clinical manifestations of sarcoidosis are often nonspecific, and the diagnosis may require a multidisciplinary approach, including radiographic testing and clinical evaluation 1

From the Research

Cell Types Implicated in Inflammatory Response

  • Macrophages and T lymphocytes play key roles in the inflammatory response in sarcoidosis, with sometimes overlapping cytokine production (i.e., TNFα and IFN-γ) but also with unique mediators that influence the pathologic picture 2
  • Alveolar macrophages in patients with sarcoidosis have reduced activity and a decreased level of PPAR-γ, which may contribute to increased inflammation and immune responses 3
  • Neutrophils and macrophages have been implicated in the inflammatory response in chronic obstructive pulmonary disease (COPD), but this may not be directly relevant to pulmonary sarcoidosis 4

Inflammatory Pathways in Sarcoidosis

  • The inflammatory pathway in sarcoidosis is complex and involves the interplay of intrinsic genetic factors, innate immunity, and adaptive immune responses to external triggers 2
  • The distinction between isolated thoracic lymphadenopathy and pulmonary involvement matters, with morbidity often higher and long-term outcomes worse for the latter 5
  • The pathogenesis of pulmonary sarcoidosis may differ in important ways from other sarcoidosis manifestations, with recent advances highlighting the role of serum amyloid A and other host factors that contribute to alterations in innate immunity 5

Pulmonary Sarcoidosis

  • Pulmonary sarcoidosis is characterized by diverse organ system manifestations, a variable clinical course, and a predilection for affecting relatively young adults worldwide 6
  • Abnormalities on chest radiographs are detected in 85% to 95% of patients who have sarcoidosis, with approximately 20% to 50% of patients presenting with respiratory symptoms 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Inflammatory Pathways in Sarcoidosis.

Advances in experimental medicine and biology, 2021

Research

Inflammatory cells and chronic obstructive pulmonary disease.

Current drug targets. Inflammation and allergy, 2005

Research

Pulmonary sarcoidosis.

Clinics in chest medicine, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.